Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- uPAR microexpression
研究概览
简要总结
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.
详细描述
- Sections of the tumor tissue will be HE stained.
- Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry.
- Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern.
- A semiqualitative scale corresponding to the level of uPAR expression will be made.
- Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern.
- An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years old.
- •Patients who underwent curatively intended surgery for gastroesophageal cancer
- •Patients who underwent surgery after 01-01-2016.
排除标准
- •Patients who applied for an exception from medical research at the "National Registry of Tissue Use."
- •Patients with other histological subtypes than adenocarcinoma.
结局指标
主要结局
uPAR microexpression
时间窗: Up to 6 months
Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively. This will be done by a pathology analysis of gastroesophageal cancer resections.
Tumor-to-background ratio
时间窗: Up to 6 months
A pathology staining will determine the uPAR in the tumor compared with the healthy cells.
次要结局
- uPAR in patient groups(Up to 6 months)
研究者
Michael Patrick Achiam
Consultant, MD, DMSci, Ph.D., FEBS-OG, Ass. Professor
Rigshospitalet, Denmark